Journal article
Efficacy and determinants of response to her kinase inhibition in her2-mutant metastatic breast cancer
LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, GI Shapiro, D Juric, IA Mayer, CL Arteaga, MI de la Fuente, AM Brufksy, I Spanggaard, M Mau-Sørensen, M Arnedos, V Moreno, V Boni, J Sohn, LS Schwartzberg Show all
Cancer Discovery | AMER ASSOC CANCER RESEARCH | Published : 2020
Abstract
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HE..
View full abstractGrants
Awarded by National Science Foundation
Funding Acknowledgements
We would like to thank patients and their families for participating in this study. Editorial support, not including writing, was provided by L. Miller and D. Carman (Miller Medical Communications Ltd.). This work was funded by Puma Biotechnology. M. Scaltriti is funded by NIH grant R01 CA190642, the Breast Cancer Research Foundation, Stand Up To Cancer (Cancer Drug Combination Convergence Team), the V Foundation, and the National Science Foundation. Authors from Memorial Sloan Kettering were funded by NIH grant P30 CA008748.